# Study of the Effects of Fabrazyme Treatment on Lactation and Infants

> **NCT00230607** · PHASE4 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 7 (actual)

## Conditions studied

- Fabry Disease
- Alpha Galactosidase A Deficiency

## Interventions

- **DRUG:** agalsidase beta

## Key facts

- **NCT ID:** NCT00230607
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05-28
- **Primary completion:** 2024-02-09
- **Final completion:** 2024-02-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Per FDA decision, the 2003 Post Marketing commitment has been fulfilled.
- **Last updated:** 2024-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230607, "Study of the Effects of Fabrazyme Treatment on Lactation and Infants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00230607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*